Clinical Trials Logo

Cold Agglutinin Disease (CAD) clinical trials

View clinical trials related to Cold Agglutinin Disease (CAD).

Filter by:
  • None
  • Page 1

NCT ID: NCT05791708 Recruiting - Clinical trials for Cold Agglutinin Disease (CAD)

Cold Agglutinin Disease Real World Evidence Registry

CADENCE
Start date: December 12, 2019
Phase:
Study type: Observational [Patient Registry]

This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 [NCT02502903,CAD patients], BIVV009-03/EFC16215 [NCT03347396], and BIVV009-04/EFC16216 [NCT03347422]) and who either completed or discontinued the corresponding clinical trial are eligible to participate in the registry.

NCT ID: NCT05086744 Active, not recruiting - Clinical trials for Immune Thrombocytopenia (ITP)

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Start date: December 21, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of iptacopan in participants with autoimmune benign hematological disorders such as primary immune thrombocytopenia and primary cold agglutinin disease.

NCT ID: NCT02502903 Completed - Clinical trials for End-stage Renal Disease (ESRD)

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders

BIVV009-01
Start date: July 13, 2015
Phase: Phase 1
Study type: Interventional

Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder, and Part E, a multiple dose (MD) study in patients with cold agglutinin disease previously treated with BIVV009 within the scope of a BIVV009 clinical trial or named patient program use. Note: For parts A-C as well as at the start of part E, study drug was named TNT009. The study drug name is changed to BIVV009 with final version Final 15.0 of the clinical study protocol.